





Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation

Amir Soltani¹, Malik Q. Mahmood², David W. Reid³ and E. Haydn Walters¹

Affiliations: ¹Medical School, University of Tasmania, Hobart, Australia. ²School of Medicine, Deakin University, Waurn Ponds, Australia. ³QIMR-Berghofer Institute of Medical Research and University of Queensland, Brisbane, Australia.

Correspondence: E. Haydn Walters University of Tasmania, Discipline of Medicine, Private Bag 34, Hobart, 7001, Australia. E-mail: haydn.walters@utas.edu.au

@ERSpublications

COPD is an independent risk factor for lung cancer. Studies have suggested that inhaled corticostroids have reduced the incidence of lung cancer in these patients. This effect is likely related to modification of epithelial-mesenchymal transition (EMT). http://bit.ly/2Km4VK4

Cite this article as: Soltani A, Mahmood MQ, Reid DW, *et al.* Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation. *Eur Respir J* 2019; 54: 1901088 [https://doi.org/10.1183/13993003.01088-2019].

This single-page version can be shared freely online.

To the Editor:

The article published by RAYMAKERS *et al.* [1] presents a lung cancer-protective effect of inhaled corticosteroids (ICS) in patients with COPD. The authors suggest that this effect is due to "anti-inflammatory" properties of ICS on the airways. This may be partly true but, from what we have come to know of COPD pathogenesis, the situation is likely to be more nuanced and complicated than that.